Amphastar Pharmaceuticals... (AMPH)
| Bid | 28.35 |
| Market Cap | 1.36B |
| Revenue (ttm) | 725.08M |
| Net Income (ttm) | 158.44M |
| EPS (ttm) | 3.06 |
| PE Ratio (ttm) | 9.3 |
| Forward PE | 9.06 |
| Analyst | Hold |
| Ask | 29.9 |
| Volume | 370,986 |
| Avg. Volume (20D) | 632,971.6 |
| Open | 28.50 |
| Previous Close | 28.29 |
| Day's Range | 28.07 - 28.64 |
| 52-Week Range | 25.89 - 53.96 |
| Beta | 0.77 |
About AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Eno...
Analyst Forecast
According to 3 analyst ratings, the average rating for AMPH stock is "Hold." The 12-month stock price forecast is $43.5, which is an increase of 52.90% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · accessnewswire.com
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Oper...
3 weeks ago · seekingalpha.com
Amphastar Pharmaceuticals Inc. (AMPH) Q4 2024 Earnings Call TranscriptAmphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications Willia...
